DGAP-News: Celesio AG: Celesio announces results for short

DGAP-News: Celesio AG / Key word(s): Final Results Celesio AG: Celesio announces results for short fiscal year 2015 17.06.2015 / 10:00 --------------------------------------------------------------------- Celesio announces results for short fiscal year 2015 Stuttgart, 17 June 2015. Celesio generated group revenue of 5,269.1 million euro in short fiscal year 2015 ended 31 March, 2015, up 5.6 per cent on the previous-year period figure of 4,990.2 million euro. Overall positive exchange rate effects amounted to 142.2 million euro, mainly related to the British pound. Adjusted earnings before interest and taxes (EBIT) fell by 19.9 per cent from 98.0 million euro in the previous year period to 78.6 million euro driven by the impact of state-imposed price reductions in the United Kingdom, weak market condition in France and the loss of a hospital contract in Norway. Performance in the divisions Revenue in the Consumer Solutions division - the pharmacy business - increased by 13.1 per cent in short fiscal year 2015 from 865.6 million euro in the previous year period to 979.0 million euro. The performance was supported by overall positive currency exchange rate effects, driven by market growth and growth from service agreements with hospitals in the United Kingdom. Thereby overall positive exchange rate effects amounted to 62.0 million euro, mainly related to the British pound sterling. After adjustments for non-recurring effects, EBIT decreased by 11.2 per cent from the previous year's figure of 52.7 million euro to 46.8 million euro in short fiscal year 2015. Some larger one-offs such as the write of an IT project in the United Kingdom led to a substantial decrease in EBIT. Revenue in the Pharmacy Solutions division - the wholesale business - increased by 4.0 per cent from 4,124.6 million euro to 4,290.1 million euro. A strong flu season and the gain of an exclusive distribution contract with a major manufacturer in the United Kingdom and overall positive currency effects of 80.2 million euro from the British pound have contributed to this growth. After adjustments for special effects, EBIT decreased by 4.9 per cent from 67.5 million euro in the previous year period to 64.2 million euro in short fiscal year 2015.The negative effect of the loss of the hospital contract in Norway as well as the weak market conditions in France weighed on EBIT. Overall positive currency effects, mainly caused by the British pound, amounted to EUR 3.0m. Earnings forecast As previously announced, full-year and prior-year results for the Brazilian businesses, Panpharma and Oncoprod, are reported as discontinued operations. With the exception of the decision to place our Brazilian business for sale, the outlook for our continued operations remains unchanged from our previous guidance. The following forecasts are based on the assumption of relatively stable exchange rates and interest rates, when compared to fiscal 2014. Overall, the Management Board of Celesio assumes that revenue from continued operations for fiscal 2016 will be flat compared to the adjusted fiscal 2014 as solid growth in Germany and the United Kingdom will be offset by continued weakness in France and the loss of a large hospital contract in Norway. The adjusted EBIT for continued operations for fiscal 2016 will be considerably below the level of the adjusted fiscal 2014 due to a non-recurring pension benefit in fiscal 2014 in Norway. The impact of the expected sale of the Brazilian businesses along with the anticipated impact of combined McKesson and Celesio procurement synergies are excluded from the 2016 outlook. <pre> Key figures of the 1st short Change on EUR Celesio Group quarter fiscal 2015 basis in % 2014 Continuing operations Revenue EUR m 4,990.2 5,269.1 5.6 EBIT EUR m 91.0 62.2 -31.6 adjusted1) EUR m 98,0 78.6 -19.9 Net profit/loss EUR m 46.7 33.0 -29.3 adjusted1) EUR m 53.7 47.7 -11.2 Free cash flow EUR m -132.0 -84.1 36.3 Retail pharmacies3) 2,180 2,184 / Wholesale branches3) 108 108 / Discontinued operations Net profit/loss EUR m -3.6 -255.3 >-100 Continuing and discontinued operations Net Financial Debt EUR m 934.22) 897.03) -4.0 Net Financial Debt/ EBITDA adj. 1) 4) 5) 1.712) 1.683) / Employees3) 38,581 38,404 / Net profit/loss EUR m 43.1 -222.3 / Earnings per share EUR 0.22 -1.10 / (basic) </pre> 1) Adjusted for special effects from defined non-recurring expenses and income (including tax effect). 2) Closing figures as at 31 December/31 March. 3) Closing figures at the end of the reporting period. 4) Based on EBITDA of the last twelve months. 5) Previous year figures as reported. Press Contact Marc Binder, Celesio AG, +49 (0) 711.5001-380 media@celesio.com Rainer Berghausen, Celesio AG, +49 (0) 711.5001-549 media@celesio.com Investor Relations Michael Otto, Celesio AG, +49 (0) 711.5001-635 investor@celesio.com Creditor Relations Tobias Mommertz, Celesio AG, +49 (0) 711.5001-395 finance@celesio.com About the Celesio Group Celesio is a leading international wholesale and retail company and provider of logistics and services to the pharmaceutical and healthcare sectors. The proactive and preventive approach ensures that patients receive the products and support that they require for optimum care. With more than 38,000 employees, Celesio operates in 14 countries around the world. Every day, the group serves over 2 million customers - at about 2,200 pharmacies of its own and over 4,300 participants in brand partnership schemes. With 133 wholesale branches, Celesio supplies 65,000 pharmacies and hospitals every day with up to 130,000 pharmaceutical products. The services benefit a patient pool of about 15 million per day. McKesson Corporation, San Francisco, USA, is the majority shareholder in Celesio AG. The company acquired more than 75 percent of Celesio AG shares in February 2014. McKesson provides solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services. --------------------------------------------------------------------- 17.06.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Celesio AG Neckartalstr. 155 70376 Stuttgart Germany Phone: +49 (0)711 5001-735 Fax: +49 (0)711 5001-740 E-mail: investor@celesio.com Internet: www.celesio.com ISIN: DE000CLS1001 WKN: CLS100 Indices: MDAX Listed: Regulated Market in Berlin, Dusseldorf, Frankfurt (Prime Standard), Munich, Stuttgart; Regulated Unofficial Market in Hamburg, Hanover; Terminbörse EUREX End of News DGAP News-Service --------------------------------------------------------------------- 369091 17.06.2015